Followers | 0 |
Posts | 69 |
Boards Moderated | 0 |
Alias Born | 02/14/2021 |
Monday, February 15, 2021 7:18:59 PM
Yeah, I don't see it that way at all. In fact, taking the "wait for publication" route that you and so many here think they are doing would be highly unusual. It's not the way it is usually done, and that in itself is a major strike against its probability. No matter how much one believes they are "waiting on publication", you are kidding yourself or disingenuous if you deny this simple truth.
Deviating from the normal course of announcing TLD and seeking approval would be taking a risk, and it would seem an unnecessary risk if the data were good. You can always release TLD and then go for the publication later, so why haven't they done that? Taking such an unorthodox risk would not seem advisable or likely, unless . . .
The results are bad. If the results are bad, then I could see waiting on a publication in order to add as much context to the bad data as possible, and then hope for the best. Now, I would buy that as a likely explanation, and it would also explain why they aren't saying anything to shareholders.
If the data were really good, though, there's just no way they would be sitting on it for months now. Nothing anyone can say will convince me otherwise because that would be a unicorn, and I don't believe in unicorns.
Hope I am wrong, but your explanation seems to be fitting a lot of square pegs into round holes in order to reach the desired conclusion. When you step back and look at things rationally from a wider perspective, waiting for months on a publication when you are holding great biomedical news that will immediately save lives makes neither logical nor common sense, and, frankly, it just isn't done that way.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM